Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.

The AI State of Play 2025 highlights a watershed year where AI-discovered molecules achieved Phase I clinical success rates of 80-90%, significantly outperforming the historical average of 40-65%. The report identifies five structural pillars: Big Pharma "AI Factories": Companies like Eli Lilly and Pfizer are building massive internal computational infrastructures and reducing discovery timelines for small molecules to just 30 days. TechBio Maturity: Companies like Insilico Medicine achieved a "Penicillin Moment" with positive Phase 2a results for the first entirely AI-native drug. Democratized Modeling: Open-source tools like Boltz-2 and OpenFold3 have commoditized high-accuracy molecular modeling. The "Agentic" Shift: A move toward autonomous systems that can independently formulate hypotheses and execute experiments. Regulatory Adaptation: Increased focus on biologics (13-year protection) over small molecules (9-year protection) due to the Inflation Reduction Act (IRA). Download the AI State of Play 2025 to learn more: https://drive.google.com/file/d/1a6etlnbgWyC2PbZIZGGXWLCJ-saA4BSO/view?usp=drive_link

What does the "State of Play" look like for the biotech and pharma industry in 2025? In this explainer, we take a look at some of the changes over the last year—from a resurgence in funding for high-value assets to the incredible speed of AI-driven drug discovery (did you know Pfizer is hitting 30-day discovery cycles?). For more details, read our free State of Play 2025 whitepaper. https://drive.google.com/file/d/1E1y6RRas74I2a4A1lFhZwZE2F9sDQucH/view?usp=drive_link

The whitepaper explores the impact of digital transformation on small molecule drug discovery, highlighting strategies to enhance R&D efficiency and reduce costs. It includes case studies,and practical approaches aimed at boosting capital efficiency and accelerating the delivery of innovative therapies to patients. What you'll learn in the whitepaper: Digital transformation is the process of applying technologies like AI, automation and advanced analytics to fundamentally change drug discovery, in ways that measurably reduce costs and timelines, improve capital efficiency and create a more lean and agile research organization. This paper provides case studies, and practical strategies to drive -

A retreat from investments in drugs and vaccines leaves U.S. less prepared for the next viral scourge, experts warn

Tests of large language models reveal that they can behave in deceptive and potentially harmful ways. What does this mean for the future?

YouTube video by Aspen Biosciences

YouTube video by Aspen Biosciences

The whitepaper explores the impact of digital transformation on small molecule drug discovery, highlighting strategies to enhance R&D efficiency and reduce costs. It includes case studies,and practica...

Recipients Schreiber and Schultz will each receive $500K prize for work on chemical probes, unnatural amino acids, and new therapeutics

The MAHA commission's assessment of children's health mirrored RFK Jr.'s familiar targets. The question now is what remedies they will recommend.

YouTube video by Recursion